Baseline disease characteristics among patients with chronic rhinosinusitis with nasal polyps in AROMA: A global registry study
Authors:
Open Access
- 1 September 2025
- journal article
- research article
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 46 (5) , 414-421
Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease of the nasal and paranasal sinuses. In phase III clinical trials, dupilumab significantly improved objective and patient-reported measures of CRSwNP versus placebo. However, a real-world evidence gap exists between efficacy and effectiveness data for dupilumab in CRSwNP, particularly in the United States. Objective: Assessing Long-teRm Outcomes of dupiluMAb Treatment in Adult Patients With CRSwNP (AROMA) aims to characterize patients who receive dupilumab for CRSwNP in a real-world setting and evaluate long-term effectiveness. Methods: AROMA is a prospective global registry study that is recruiting adult patients with uncontrolled CRSwNP who were initiating dupilumab and following them for up to 36 months. Baseline demographics and disease characteristics were assessed for all patients entering the registry. Results: As of February 2023, the study had recruited 303 patients of a target enrollment of 700, with a mean age of 50.8 years, and 57.1% were recruited in the United States. A history of asthma was reported in 70.6% of the patients and a history of allergic rhinitis in 70.6% of the patients. In the 24 months before enrollment, 61.7% of the patients had at least one sinonasal surgery and 68.6% used systemic corticosteroids. At baseline, 35.0% of the patients were receiving intranasal corticosteroids and 33.3% were receiving leukotriene receptor antagonists. In the Global Patient Assessment, 31.7% and 29.7% of the patients reported moderate and severe CRSwNP symptoms, respectively, during the past week. Conclusion: Patients in AROMA had a high disease burden in terms of symptoms, comorbidities, and treatment burden. Nearly two-thirds of patients with CRSwNP had at least one sinonasal surgery before initiating dupilumab.Clinical trial NCT04959448 (AROMA), www.clinicaltrials.govKeywords
This publication has 15 references indexed in Scilit:
- Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real‐life study (DUPIREAL)Allergy, 2023
- Real‐life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polypsAllergy, 2021
- Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Respiratory Medicine, 2021
- Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposisCurrent Medical Research and Opinion, 2020
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trialsJournal of Allergy and Clinical Immunology, 2020
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polypsThe Laryngoscope, 2019
- Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory DiseaseThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Revisiting Type 2‐high and Type 2‐low airway inflammation in asthma: current knowledge and therapeutic implicationsClinical & Experimental Allergy, 2017
- Aspirin-Exacerbated Respiratory Disease — New Prime SuspectsNew England Journal of Medicine, 2016